Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ranbaxy

- PMLiVE

Depot Abilify approval in US buoys Lundbeck and Otsuka

FDA licences the once-monthly version of Lundbeck's blockbuster schizophrenia drug

- PMLiVE

Lundbeck’s alcohol dependency drug approved in Europe

Selincro is the first drug approved to reduce alcohol consumption

- PMLiVE

Mylan agrees $1.6bn deal to buy Agila injectables unit

Generics firm becomes “top three player” in injectables

- PMLiVE

Actavis sales rise but profits slump as Lipitor effect recedes

Reports first set of results since merger with Watson

- PMLiVE

Gilead settles patent dispute with Teva over Viread generic

Launch of generic HIV drug held back until December 2017

- PMLiVE

Former Nycomed CEO Hakan Bjorklund to chair Lundbeck

Mats Pettersson to step down in March

Teva facing $2bn liability for at-risk generic Protonix launch

Potential litigation costs from Pfizer are triple the generics firm's original estimates

Mylan to develop Lantus, Humalog and NovoLog generics

Signs Indian biotech deal to compete with the big-selling insulin brands

- PMLiVE

Teva wins challenge to BMS’ Baraclude patent in US

US court says hepatitis B treatment’s patent is invalid

Mylan appoints two new board members

Melina Higgins is a former partner at Goldman Sachs and Rajiv Malik is president at Mylan

- PMLiVE

Merck blocks Mylan’s generic Zetia and Vytorin after appeal

Keeps patents of cholesterol medicines protected until April 2017

- PMLiVE

Lundbeck looks to new products as Lexapro slumps

Denmark-based pharma company reports flat sales during fourth quarter of 2012

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links